ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals
1. Strategic Objectives of the Acquisition
ONO, as a Global Specialty Pharma company, is committed to delivering innovative new drugs to patients around the world. As a part of our medium-term management plan, ONO aims to reinforce our pipeline and accelerate global development, as well as realize direct sales in
Deciphera focuses on the discovery, development, and commercialization of innovative medicines for cancer and has deep expertise in kinase biology (see Table 1 below). QINLOCK® (ripretinib), a KIT inhibitor, is approved in over 40 countries and marketed globally, including in the US,
With this Acquisition, ONO will expand its oncology pipeline with near-term revenue growth, notably through the immediate addition of QINLOCK® and potential addition of vimseltinib. Moreover, acquiring Deciphera's commercial capabilities in
2. Overview of the Acquisition
The Acquisition is structured as a tender offer and subsequent merger of Deciphera with a wholly-owned subsidiary of ONO. Under the terms of the merger agreement, ONO will acquire all outstanding shares of Deciphera at a price of US
3. Overview of Deciphera
(1) |
Company |
|
|||
(2) |
Address |
200 Smith Street |
|||
(3) |
Representative's |
President & CEO, |
|||
(4) |
Business Description |
R&D and Commercialization of pharmaceuticals |
|||
(5) |
|
US |
|||
(6) |
Year of Establishment |
2017
(initial company |
|||
(7) |
Major shareholders and
(as of |
Blackrock Inc.: 7.3%
|
|||
(8) |
Relationship between ONO and Deciphera |
Capital Relationship |
N.A. |
||
Personal Relationship |
N.A. |
||||
Business Relationship |
N.A. |
||||
Status of A |
N.A. |
||||
(9) |
Deciphera's consolidated operating results and consolidated financial position for the past three |
||||
Accounting Period (Unit: thousands of US $) |
Fiscal year ended |
Fiscal year ended |
Fiscal year ended |
||
|
Total Equity |
304,720 |
341,691 |
350,916 |
|
|
Total Assets |
429,484 |
454,039 |
473,566 |
|
|
Equity per share (US $)(*2) |
5.25 |
4.53 |
4.13 |
|
|
Revenue |
96,148 |
134,036 |
163,356 |
|
|
Operating Loss |
(300,077) |
(182,722) |
(210,958) |
|
|
Net Loss |
(299,964) |
(178,931) |
(194,942) |
|
|
Net loss per share (US $) |
(5.16) |
(2.37) |
(2.29) |
|
|
Dividend per share (US $) |
- |
- |
- |
|
|
|
|
|
|
|
(*1) Information from Deciphera's Annual Report on Form 10-K, for the fiscal year ended December |
|||||
(*2) Calculated by total equity divided by weighted average common shares outstanding. |
Table.1 Deciphera's Development Pipeline
Products |
Mode of Action |
Indication |
Stage |
QINLOCK |
KIT inhibitor |
4L GIST, 2L GIST (KIT Exon 11+17/18) |
Approved, P3 |
Vimseltinib |
CSF-1R inhibitor |
TGCT, cGVHD |
Regulatory Submission, |
DCC-3116 |
ULK inhibitor |
KRAS mutated cancer, GIST |
P1b |
DCC-3084 |
Pan-RAF inhibitor |
Solid Tumors and Hematologic Malignancies |
P1 preparation |
DCC-3009 |
Pan-KIT inhibitor |
GIST |
IND-enabling |
4. Number of shares to be acquired, acquisition price, and status of shareholdings before and
after the Acquisition
(1) |
Number of shares already acquired |
0 shares (Percentage of voting rights: 0%) |
(2) |
Number of shares to be acquired(*3) |
94,721,482 shares |
(3)
|
Transaction consideration
|
US |
(4) |
Number of shares held after the |
94,721,482 shares (Percentage of voting rights: 100%) |
|
|
|
(*3) Based on fully diluted shares of common stock outstanding as of |
5. Schedule
(1) |
Signing date |
|
(2) |
Estimated Completion of acquisition |
Second quarter of ONO's fiscal year 2024 |
6. Financial Impact of the Acquisition
ONO is still reviewing the impact and will promptly announce any events that are to be publicly reported.
7. About QINLOCK ®
QINLOCK® is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib in
8. About Vimseltinib
Tenosynovial giant cell tumor (TGCT) is a locally aggressive tumor that occurs inside or near joints. Surgical excision of the tumor is often used as the first line of therapy., but recurrence is common and systemic treatment options are limited. There is significant unmet medical need for new treatment options with improved efficacy and safety. TGCT is driven by a genetic translocation of the colony-stimulating factor 1 (CSF-1) gene and resultant overexpression of CSF-1. Vimseltinib is a highly potent and selective CSF-1 receptor inhibitor that has received Fast Track designation from the FDA, and demonstrated statistically significant and clinically meaningful efficacy across all primary and secondary endpoints in the Phase III MOTION trial in patients with tenosynovial giant cell tumor (TGCT).
View original content to download multimedia:https://www.prnewswire.com/news-releases/ono-enters-into-a-definitive-agreement-to-acquire-deciphera-pharmaceuticals-302131290.html
SOURCE